Clinical trial details

A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE

Identifier

516-005

Sponsor

MIRATI THERAPEUTICS, INC.

Principal Investigator

ENRIQUETA FELIP FONT

Service

Oncology

Study details

Tumor type: LUNG-NSCLC
Stage: Advanced
Main Investigational Agent : Targeted therapy
Phase: III
Randomization: Randomized

Molecular details

Biomarker: Not applicable
Biomarker criteria: Not applicable
Prescreening: Not applicable
Additional study population requirements: Not applicable

Drug details

Arm A: Docetaxel
Arm B: Nivolumab and Sitravatinib

Links

Clinical Trials GOV (NCT identifier): NCT03906071
EU Clinical Trials Register (eudraCT Identifier): 2019-001043-41